Last Updated : May 7, 2024
The latest CADTH Reimbursement Review reports are posted to this page. CADTH reimbursement reviews are comprehensive assessments of the clinical effectiveness and cost-effectiveness, as well as patient and clinician perspectives, of a drug or drug class. The assessments inform non-binding recommendations that help guide the reimbursement decisions of Canada's federal, provincial, and territorial governments, with the exception of Quebec. Implementation advice and funding algorithms are provided where applicable.
| Brand Name | Generic Name | Therapeutic Area | Recommendation Type | Project Status Sort descending | Date Submission Received | Date Recommendation Issued |
|---|---|---|---|---|---|---|
| Simponi | Golimumab | Arthritis, Rheumatoid | List in a similar manner | Complete | ||
| Cimzia | Certolizumab pegol | Arthritis, rheumatoid | Do not list | Complete | ||
| Soliris | Eculizumab | Paroxysmal nocturnal hemoglobinuria (PNH) | Do not list | Complete | ||
| Multaq | Dronedarone hydrochloride | Atrial fibrillation | Do not list | Complete | ||
| Nplate | Romiplostim | Chronic immune (idiopathic) thrombocytopenic purpura (ITP) | Do not list | Complete | ||
| Januvia | Sitagliptin phosphate | Diabetes mellitus (Type 2) | List with clinical criteria and/or conditions | Complete | ||
| Janumet | Sitagliptin phosphate monohydrate / metformin hydrochloride | Diabetes mellitus (Type 2) | List with clinical criteria and/or conditions | Complete | ||
| Abilify | Aripiprazole | Schizophrenia | Do not list | Complete | ||
| Onglyza | Saxagliptin | Diabetes mellitus (Type 2) | Do not list | Complete | ||
| Lotemax | Loteprednol etabonate | Post-operative inflammation following cataract surgery | Do not list | Complete |
Last Updated : May 7, 2024